TrialLancet (London, England)2018

Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.